May Health, a medical device company focused on expanding treatment options for women living with polycystic ovary syndrome (PCOS), announced that it has raised €10 million (about $11.7 million) in new funding. The round included participation from existing investors Sofinnova Partners, Trill Impact, and Bpifrance, along with new investor Nexpring Health.
The company plans to use the funding to complete its pivotal U.S. Investigational Device Exemption (IDE) clinical trial called REBALANCE and to support commercialization planning in Europe for its Anavi System. The device previously received CE Mark certification under the European Union’s Medical Device Regulation in October 2025.
PCOS affects approximately 10–13% of women worldwide and is the most common endocrine disorder among women of reproductive age. It is also a leading cause of female infertility, often preventing consistent ovulation. May Health’s Anavi System is designed to address this issue through a one-time, office-based procedure intended to restore ovulation in women who do not respond to, cannot take, or choose not to pursue first-line fertility therapies.
The REBALANCE study is an ongoing prospective, multicenter, randomized controlled trial evaluating the safety and effectiveness of the company’s technology for restoring ovulation in women with PCOS-related infertility. The study is currently recruiting women ages 18 to 40 who have been diagnosed with PCOS and who have failed, are contraindicated for, or decline first-line ovulation-induction treatments. More than 15 fertility centers across the United States are participating in the trial.
Founded in France and headquartered in Menlo Park, California, May Health is led by a team of medical technology and women’s health executives with experience in product development, regulatory strategy, clinical validation, and commercialization. The company was previously known as Ziva Medical and Ablacare and evolved through the Paris-based accelerator MD Start.
KEY QUOTES:
“For too long, women with PCOS-related infertility have needed more options to support their family-building journey. With the continued support of our existing investors, we are making significant progress enrolling the REBALANCE trial and preparing to bring the Anavi System to market in Europe and the United States. We are pleased to welcome Nexpring Health to the syndicate, and we celebrate the strong mission alignment between our organizations.”
Colby Holtshouse, President And Chief Executive Officer Of May Health
“May Health is addressing a critical gap in modern infertility care. By targeting the underlying drivers of PCOS-related infertility, the company is reshaping the treatment paradigm for millions of women worldwide. We are proud to support a world-class team advancing meaningful progress in women’s healthcare.”
Antoine Papiernik, Chairman And Managing Partner Of Sofinnova Partners
“At Nexpring Health, we believe our role as a global leader in ART solutions goes beyond the products we make. It’s about advancing fertility care in every way we can, for the clinicians on the front lines, for the embryologists working tirelessly in the lab, and ultimately, for the patients whose hopes and dreams depend on this progress. May Health is doing exactly the kind of work that can change patient outcomes, expand clinical options, and move this field forward, and we are proud to stand with them.”
Wil Boren, Chief Executive Officer Of Nexpring Health
